ArticleJournal of animal science2025
Dietary zinc-di-tripeptide enhances zinc relative bioavailability and reduces fecal zinc losses compared to zinc sulfate, without compromising performance of growing pigs.
Article in Journal of animal science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc (Zn) is an essential trace mineral involved in key physiological processes, and organic Zn sources are proposed to have higher bioavailability than inorganic forms. This study aimed to evaluate the bioavailability of a Zn-di-tripeptide (Zn-di-tripep) chelate compared to Zn sulfate (ZnSO4) on growth performance, apparent total tract digestibility of Zn and Zn concentrations in feces, serum, liver, and bone in growing pigs. Ninety male pigs (Landrace × Large White, 63 day-old, 25.44 ± 0.302 kg body weight [BW]) were used in a randomized complete block design based on BW with 10 pigs per treatment over a 60-day period. Pigs were allocated to a 2 × 4 + 1 factorial design, composed by 2 Zn sources (Zn-di-tripep vs. ZnSO4), 4 levels of dietary Zn (30, 60, 90, and 120 mg/kg diet), and a negative control (no supplemental Zn). Digestibility was assessed using acid-insoluble ash as an internal marker, and relative bioavailability was estimated by linear slope-ratio regression. Data were analyzed using Zn source and level as fixed effects, blocks as random effects, and linear and quadratic polynomial contrasts to assess dose-response. Pigs fed Zn-di-tripep or ZnSO4 showed improved performance (P ≤ 0.05) compared to unsupplemented pigs, particularly for average daily gain (ADG) and average daily feed intake (ADFI). From day 0 to 30, pigs fed Zn-di-tripep exhibited a quadratic response (P ≤ 0.05) for ADG and gain-to-feed ratio (G:F), and a linear increase (P ≤ 0.05) in final BW (FBW) and ADFI. From day 30 to 60, both sources promoted linear and quadratic increases (P ≤ 0.05) in FBW, ADG, and G:F, and 120 mg Zn/kg diets resulted in better performance. Fecal Zn concentrations increased linearly (P ≤ 0.05) with dietary Zn level. Pigs fed Zn-di-tripep showed a slight decrease and increase in fecal Zn (P = 0.105) and liver Zn (P = 0.109), respectively, and higher bone Zn concentrations (P ≤ 0.05) than ZnSO4. Serum Zn increased over time (P ≤ 0.05) in all Zn-supplemented pigs, with a trend (P ≤ 0.10) toward higher concentrations in pigs fed Zn-di-tripep than ZnSO4. Apparent total tract digestibility of Zn showed linear effects (P ≤ 0.05), with positive values only for Zn-di-tripep. In conclusion, dietary Zn-di-tripep supplementation improved Zn digestibility, serum and tissue Zn concentrations, and reduced fecal excretion compared to ZnSO4, suggesting greater bioavailability by allowing a reduction in Zn supplementation (∼34%), without affecting pig performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.